'New Gold Standard' for Previously Untreated CLL

Personalized, time-limited regimen of venetoclax plus ibrutinib improves survival versus FCR

Related Keywords

United States ,United Kingdom ,Miami ,Florida ,American ,Mikkael Sekeres ,Uk National Cancer Research Institute ,American Society Of Hematology ,University Of Miami Miller School Medicine ,International Workshop On Chronic Lymphocytic Leukemia ,James University Hospital In Leeds ,Peter Hillmen ,University Hospital ,American Society ,Miami Miller School ,Cancer Research Institute ,International Workshop ,Chronic Lymphocytic Leukemia ,Managing Editor ,Medpage Today ,